These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36776304)

  • 1. Trends in incidence and survival in patients with gastrointestinal neuroendocrine tumors: A SEER database analysis, 1977-2016.
    Liu M; Wei L; Liu W; Chen S; Guan M; Zhang Y; Guo Z; Liu R; Xie P
    Front Oncol; 2023; 13():1079575. PubMed ID: 36776304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis.
    Tsikitis VL; Wertheim BC; Guerrero MA
    J Cancer; 2012; 3():292-302. PubMed ID: 22773933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in Incidence and Survival of Patients with Pancreatic Neuroendocrine Neoplasm, 1987-2016.
    Wang J; Liu J; He C; Sun T; Yan Y; Che G; Li X; Sun H; Ma H
    J Oncol; 2021; 2021():4302675. PubMed ID: 34976056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognosis of patients with neuroendocrine tumor: a SEER database analysis.
    Man D; Wu J; Shen Z; Zhu X
    Cancer Manag Res; 2018; 10():5629-5638. PubMed ID: 30519109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
    JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
    Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
    JAMA Oncol; 2017 Oct; 3(10):1335-1342. PubMed ID: 28448665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database.
    Punekar SR; Kaakour D; Masri-Lavine L; Hajdu C; Newman E; Becker DJ
    Am J Clin Oncol; 2020 Dec; 43(12):846-849. PubMed ID: 32910023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival Improvement in Patients with Renal Cell Carcinoma and Disparities between Different Sexes, Races, and Socioeconomic Status: 1977-2016.
    Ouyang D; Sun H; Chen N; Yan Y; Ma H; Xia J
    J Oncol; 2022; 2022():1587365. PubMed ID: 35942409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a nomogram model to predict survival outcomes in patients with primary hepatic neuroendocrine tumors based on SEER database.
    Zhang Z; Zhao X; Li Z; Wu Y; Liu Y; Li Z; Li G
    BMC Cancer; 2021 May; 21(1):567. PubMed ID: 34006241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant neuroendocrine tumors: incidence and outcomes in pediatric patients.
    Allan B; Davis J; Perez E; Lew J; Sola J
    Eur J Pediatr Surg; 2013 Oct; 23(5):394-9. PubMed ID: 23444065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study.
    Zhou H; Zhang Y; Wei X; Yang K; Tan W; Qiu Z; Li S; Chen Q; Song Y; Gao S
    Cancer Med; 2017 Nov; 6(11):2745-2756. PubMed ID: 28980417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated population-based review of carcinoid tumors.
    Maggard MA; O'Connell JB; Ko CY
    Ann Surg; 2004 Jul; 240(1):117-22. PubMed ID: 15213627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fluctuating incidence, improved survival of patients with breast cancer, and disparities by age, race, and socioeconomic status by decade, 1981-2010.
    Lu G; Li J; Wang S; Pu J; Sun H; Wei Z; Ma Y; Wang J; Ma H
    Cancer Manag Res; 2018; 10():4899-4914. PubMed ID: 30464592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971.
    Ellis L; Shale MJ; Coleman MP
    Am J Gastroenterol; 2010 Dec; 105(12):2563-9. PubMed ID: 20823835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pathological characteristics and prognosis of 132 cases of rectal neuroendocrine tumors.
    Yu YJ; Li YW; Shi Y; Zhang Z; Zheng MY; Zhang SW
    World J Gastrointest Oncol; 2020 Aug; 12(8):893-902. PubMed ID: 32879666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-functional pancreatic neuroendocrine tumours: emerging trends in incidence and mortality.
    Wu J; Sun C; Li E; Wang J; He X; Yuan R; Yi C; Liao W; Wu L
    BMC Cancer; 2019 Apr; 19(1):334. PubMed ID: 30961556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastric Neuroendocrine Tumors (G-Nets): Incidence, Prognosis and Recent Trend Toward Improved Survival.
    Yang Z; Wang W; Lu J; Pan G; Pan Z; Chen Q; Liu W; Zhao Y
    Cell Physiol Biochem; 2018; 45(1):389-396. PubMed ID: 29402806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study.
    Cai W; Tan Y; Ge W; Ding K; Hu H
    Cancer Med; 2018 Jun; 7(6):2699-2709. PubMed ID: 29733523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia.
    Wyld D; Wan MH; Moore J; Dunn N; Youl P
    Cancer Epidemiol; 2019 Dec; 63():101598. PubMed ID: 31539715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends of incidence and survival in patients with gastrointestinal mucinous adenocarcinoma.
    Zong Z; Luo Y; Ying H; Wang A; Li H; Yi C
    Oncol Lett; 2018 Nov; 16(5):5791-5798. PubMed ID: 30344730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.